Pace Life Sciences Announces Successful Pre-Approval Inspection From US FDA in Lebanon, NJ - Newswire.com
Pace Life Sciences Announces Successful Pre-Approval Inspection From US FDA in Lebanon, NJ - Newswire.com — FDA update affecting Pharmaceutical Manufacturing (FDA/DEA).
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 3, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Pharmaceutical Manufacturing (FDA/DEA) (branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)) should confirm how it applies to their specific situation before acting. There is a time constraint attached: as soon as possible. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Pace Life Sciences Announces Successful Pre-Approval Inspection From US FDA in Lebanon, NJ - Newswire.com
Who it affects
Pharmaceutical Manufacturing (FDA/DEA) (branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B))
What you must do
Review the new rule now and confirm your operation stays compliant to avoid penalties or loss of standing in Pharmaceutical Manufacturing (FDA/DEA).
Deadline
as soon as possible
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- CEO Spotlight: Larry Lee - contractpharma.com
- Amgen invests $1bn into new US drug manufacturing facility - Manufacturing Chemist
- Fujifilm Holly Springs Selected for FDA PreCheck Pilot - contractpharma.com
- Catalent Announces $12 Million Expansion Program at Kansas City Facility - contractpharma.com
- Fight over GLP-1 compounding plays out in statehouses, courthouses - The Indiana Lawyer